Methamphetamine neurotoxicity increases brain expression and alters behavioral functions of CB1 cannabinoid receptors

Journal of Psychiatric Research

Volumn 44, Issue 14, 2010, Pages 944-955

  Bortolato, Marco ^a,b   Frau, Roberto ^a,b   Bini, Valentina ^b   Luesu, William ^b   Loriga, Roberta ^b   Collu, Maria ^b   Gessa, Gian Luigi ^b   Ennas, M Grazia ^b   Paola Castelli, M ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cannabinoids; Methamphetamine; Object exploration; Open field; Startle reflex

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; CANNABINOID 1 RECEPTOR; METHAMPHETAMINE; SODIUM CHLORIDE;

ACOUSTIC REFLEX; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BEHAVIORAL SCIENCE; BODY TEMPERATURE; BODY WEIGHT; BRAIN CORTEX; BRAIN REGION; CAUDATE NUCLEUS; COGNITION; CONTROLLED STUDY; EMOTION; HIPPOCAMPUS; IMMUNOFLUORESCENCE; LOCOMOTION; MALE; NEUROTOXICITY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; RAT; RECOGNITION; STARTLE REFLEX; TRANQUILIZING ACTIVITY;

EID: 77957682626     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2010.03.002     Document Type: Article

References (96)

1. Arevalo C., de Miguel R., Hernandez-Tristan R. Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology Biochemistry and Behavior 2001, 70:123-131.
2. Baek J., Zheng Y., Darlington C.L., Smith P.F. The CB receptor agonist, WIN 55,212-2, dose-dependently disrupts object recognition memory in adult rats. Neuroscience Letters 2009, 464:71-73.
3. Begg M., Pacher P., Batkai S., Osei-Hyiaman D., Offertaler L., Mo F.M., et al. Evidence for novel cannabinoid receptors. Pharmacology and Therapeutics 2005, 106:133-145.
4. Belcher A.M., Feinstein E.M., O'Dell S.J., Marshall J.F. Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharmacology 2008, 33:1453-1463.
5. Belcher A.M., O'Dell S.J., Marshall J.F. Impaired object recognition memory following methamphetamine, but not p-chloroamphetamine- or d-amphetamine-induced neurotoxicity. Neuropsychopharmacology 2005, 30:2026-2034.
6. Beltramo M., de Fonseca F.R., Navarro M., Calignano A., Gorriti M.A., Grammatikopoulos G., et al. Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. Journal of Neuroscience 2000, 20:3401-3407.
7. Berrendero F., Maldonado R. Involvement of the opioid system in the anxiolytic-like effects induced by Delta(9)-tetrahydrocannabinol. Psychopharmacology (Berl) 2002, 163:111-117.
8. Bodor A.L., Katona I., Nyiri G., Mackie K., Ledent C., Hajos N., et al. Endocannabinoid signaling in rat somatosensory cortex: laminar differences and involvement of specific interneuron types. Journal of Neuroscience 2005, 25:6845-6856.
9. Boot B.P., McGregor I.S., Hall W. MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet 2000, 355:1818-1821.
10. Bortolato M., Aru G.N., Frau R., Orru M., Luckey G.C., Boi G., et al. The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. Psychopharmacology (Berl) 2005, 177:264-271.
11. Bortolato M., Piomelli D. The endocannabinoid system and anxiety responses. Hand book of Anxiety and Fear 2008, 303-325. Elsevier, Amsterdam. R.J. Blanchard, D.C. Blanchard, G. Griebel, D. Nutt (Eds.).
12. Bortolato M., Frau R., Piras A.P., Luesu W., Bini V., Diaz G., et al. Methamphetamine induces long-term alterations in reactivity to environmental stimuli: correlation with dopaminergic and serotonergic toxicity. Neurotoxicity Research 2009, 15:232-245.
13. Braff D.L., Geyer M.A., Light G.A., Sprock J., Perry W., Cadenhead K.S., et al. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophrenia Research 2001, 49:171-178.
14. Breivogel C.S., Griffin G., Di Marzo V., Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Molecular Pharmacology 2001, 60:155-163.
15. Cadenhead K.S., Geyer M.A., Braff D.L. Impaired startle prepulse inhibition and habituation in patients with schizotypal personality disorder. American Journal of Psychiatry 1993, 150:1862-1867.
16. Cadet J.L., Sheng P., Ali S., Rothman R., Carlson E., Epstein C. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. Journal of Neurochemistry 1994, 62:380-383.
17. Chapillon P., Manneche C., Belzung C., Caston J. Rearing environmental enrichment in two inbred strains of mice: 1. Effects on emotional reactivity. Behavior Genetics 1999, 29:41-46.
18. Chiang Y.C., Chen J.C. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry 2007, 103:2505-2517.
19. Clemens K.J., Cornish J.L., Hunt G.E., McGregor I.S. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug and Alcohol Dependence 2007, 86:183-190.
20. Darke S., Kaye S., McKetin R., Duflou J. Major physical and psychological harms of methamphetamine use. Drug and Alcohol Review 2008, 27:253-262.
21. Davidson C., Gow A.J., Lee T.H., Ellinwood E.H. Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Research Brain Research Reviews 2001, 36:1-22.
22. Davidson E.S., Schenk S. Variability in subjective responses to marijuana: initial experiences of college students. Addictive Behaviors 1994, 19:531-538.
23. Dhawan J., Deng H., Gatley S.J., Makriyannis A., Akinfeleye T., Bruneus M., et al. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Synapse 2006, 60:93-101.
24. Ennaceur A., Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behavioural Brain Research 1988, 31:47-59.
25. Ernst T., Chang L., Leonido-Yee M., Speck O. Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 2000, 54:1344-1349.
26. Fergusson D.M., Horwood L.J., Swain-Campbell N. Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 2002, 97:1123-1135.
27. Fernandez-Lopez D., Martinez-Orgado J., Nunez E., Romero J., Lorenzo P., Moro M.A., et al. Characterization of the neuroprotective effect of the cannabinoid agonist WIN-55212 in an in vitro model of hypoxic-ischemic brain damage in newborn rats. Pediatric Research 2006, 60:169-173.
28. Genn R.F., Tucci S., Marco E.M., Viveros M.P., File S.E. Unconditioned and conditioned anxiogenic effects of the cannabinoid receptor agonist CP 55,940 in the social interaction test. Pharmacology Biochemistry and Behavior 2004, 77:567-573.
29. 1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. Journal of Neurophysiology 2001, 85:468-471.
30. Geyer M.A., Braff D.L. Startle habituation and sensorimotor gating in schizophrenia and related animal models. Schizophrenia Bulletin 1987, 13:643-668.
31. Gifford A.N., Bruneus M., Gatley S.J., Lan R., Makriyannis A., Volkow N.D. Large receptor reserve for cannabinoid actions in the central nervous system. Journal of Pharmacology and Experimental Therapeutics 1999, 288:478-483.
32. Gonzalez R., Rippeth J.D., Carey C.L., Heaton R.K., Moore D.J., Schweinsburg B.C., et al. Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure. Drug and Alcohol Dependence 2004, 76:181-190.
33. Grant B.F., Pickering R. The relationship between cannabis use and DSM-IV cannabis abuse and dependence: results from the national longitudinal alcohol epidemiologic survey. Journal of Substance Abuse 1998, 10:255-264.
34. Hall W., Solowij N. Adverse effects of cannabis. Lancet 1998, 352:1611-1616.
35. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11.
36. Hirata H., Ladenheim B., Rothman R.B., Epstein C., Cadet J.L. Methamphetamine-induced serotonin neurotoxicity is mediated by superoxide radicals. Brain Research 1995, 677:345-347.
37. Hopfer C.J., Young S.E., Purcell S., Crowley T.J., Stallings M.C., Corley R.P., et al. Cannabis receptor haplotype associated with fewer cannabis dependence symptoms in adolescents. American Journal of Medical Genetics Part B Neuropsychiatric Genetics 2006, 141B:895-901.
38. 1 cannabinoid receptor induction in experimental stroke. Annals of Neurology 2000, 48:257-261.
39. Kalechstein A.D., Newton T.F., Longshore D., Anglin M.D., van Gorp W.G., Gawin F.H. Psychiatric comorbidity of methamphetamine dependence in a forensic sample. Journal of Neuropsychiatry and Clinical Neurosciences 2000, 12:480-484.
40. Klamer D., Palsson E., Revesz A., Engel J.A., Svensson L. Habituation of acoustic startle is disrupted by psychotomimetic drugs: differential dependence on dopaminergic and nitric oxide modulatory mechanisms. Psychopharmacology (Berl) 2004, 176:440-450.
41. Kulsudjarit K. Drug problem in southeast and southwest Asia. Annals of the New York Academy of Sciences 2004, 1025:446-457.
42. Landa L., Slais K., Sulcova A. Impact of cannabinoid receptor ligands on behavioural sensitization to antiaggressive methamphetamine effects in the model of mouse agonistic behaviour. Neuro Endocrinology Letters 2006, 27:703-710.
43. Ludewig K., Geyer M.A., Vollenweider F.X. Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia. Biological Psychiatry 2003, 54:121-128.
44. Mailleux P., Vanderhaeghen J.J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. Journal of Neurochemistry 1993, 61:1705-1712.
45. Malone D.T., Taylor D.A. The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats. Behavioural Brain Research 2006, 166:101-109.
46. Marchalant Y., Rosi S., Wenk G.L. Anti-inflammatory property of the cannabinoid agonist WIN 55212-2 in a rodent model of chronic brain inflammation. Neuroscience 2007, 144:1516-1522.
47. Marin S., Marco E., Biscaia M., Fernandez B., Rubio M., Guaza C., et al. Involvement of the kappa-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacology, Biochemistry, and Behavior 2003, 74:649-656.
48. Marshall J.F., O'Dell S.J., Weihmuller F.B. Dopamine-glutamate interactions in methamphetamine-induced neurotoxicity. Journal of Neural Transmission General Section 1993, 91:241-254.
49. 1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 2003, 302:84-88.
50. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
51. McLaughlin P.J., Lu D., Winston K.M., Thakur G., Swezey L.A., Makriyannis A., et al. Behavioral effects of the novel cannabinoid full agonist AM 411. Pharmacology Biochemistry and Behavior 2005, 81:78-88.
52. Milani R.M., Parrott A.C., Schifano F., Turner J.J. Pattern of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Human Psychopharmacology 2005, 20:249-261.
53. Nagayama T., Sinor A.D., Simon R.P., Chen J., Graham S.H., Jin K., et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. Journal of Neuroscience 1999, 19:2987-2995.
54. 1 receptors. Naunyn Schmiedeberg's Archives of Pharmacology 2000, 361:19-24.
55. Navarro J.F., Rivera A., Maldonado E., Cavas M., de la Calle A. Anxiogenic-like activity of 3,4-methylenedioxy-methamphetamine (" Ecstasy" ) in the social interaction test is accompanied by an increase of c-fos expression in mice amygdala. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004, 28:249-254.
56. 1 receptor antagonists in rats. Psychopharmacology (Berl) 2006, 184:26-35.
57. Ohmori T., Abekawa T., Koyama T. The role of glutamate in the neurotoxic effects of methamphetamine. Annals of the New York Academy of Sciences 1996, 801:315-326.
58. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron 2001, 29:729-738.
59. Onaivi E.S., Green M.R., Martin B.R. Pharmacological characterization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics 1990, 253:1002-1009.
60. Oropeza V.C., Page M.E., Van Bockstaele E.J. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Research 2005, 1046:45-54.
61. Parks C.L., Robinson P.S., Sibille E., Shenk T., Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:10734-10739.
62. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego. third ed. 1997.
63. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Current Medicinal Chemistry 1999, 6:635-664.
64. Pertwee R.G. Pharmacological actions of cannabinoids. Handbook of Experimental Pharmacology 2005, 1:1-51.
65. Powell S.B., Geyer M.A., Gallagher D., Paulus M.P. The balance between approach and avoidance behaviors in a novel object exploration paradigm in mice. Behavioural Brain Research 2004, 152:341-349.
66. Prut L., Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. European Journal of Pharmacology 2003, 463:3-33.
67. Robinet P.M., Rowlett J.K., Bardo M.T. Individual differences in novelty-induced activity and the rewarding effects of novelty and amphetamine in rats. Behavioural Processes 1998, 1:1-9.
68. Rodriguez de Fonseca F., Carrera M.R., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science 1997, 276:2050-2054.
69. Rodriguez de Fonseca F., Rubio P., Menzaghi F., Merlo-Pich E., Rivier J., Koob G.F., et al. Corticotropin-releasing factor (CRF) antagonist [D-Phe12, Nle21,38, C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. Journal of Pharmacology and Experimental Therapeutics 1996, 276:56-64.
70. 1 receptor mRNA levels in the caudate-putamen. Life Sciences 2000, 66:485-494.
71. Rothmann R.B., Baumann M.H. Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology 2003, 479:23-40.
72. Roy V., Chapillon P. Further evidences that risk assessment and object exploration behaviours are useful to evaluate emotional reactivity in rodents. Behavioural Brain Research 2004, 154:439-448.
73. Salo R., Nordahl T.E., Natsuaki Y., Leamon M.H., Galloway G.P., Waters C., et al. Attentional control and brain metabolite levels in methamphetamine abusers. Biological Psychiatry 2007, 61:1272-1280.
74. SAMHSA. Substance abuse and mental health services administration. 2001.
75. Sanudo-Pena M.C., Tsou K., Walker J.M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sciences 1999, 65:703-713.
76. Schmidt C.J., Sonsalla P.K., Hanson G.R., Peat M.A., Gibb J.W. Methamphetamine-induced depression of monoamine synthesis in the rat: development of tolerance. Journal of Neurochemistry 1985, 44:852-855.
77. Schneider M., Koch M. The cannabinoid agonist WIN 55,212-2 reduces sensorimotor gating and recognition memory in rats. Behavioural Pharmacology 2002, 13:29-37.
78. Selden L.S. Neurotoxicity of methamphetamine: mechanisms of action and issues related to aging. NIDA Research Monographs 1991, 115:24-32.
79. 1 receptor density to G-protein activation. Journal of Neurochemistry 2001, 77:1048-1057.
80. Sharma H.S., Ali S.F. Acute administration of 3,4-methylenedioxymethamphetamine induces profound hyperthermia, blood-brain barrier disruption, brain edema formation, and cell injury. Annals of the New York Academy of Sciences 2008, 1139:242-258.
81. Simon S.L., Domier C.P., Sim T., Richardson K., Rawson R.A., Ling W. Cognitive performance of current methamphetamine and cocaine abusers. Journal of Addictive Diseases 2002, 21:61-74.
82. Solbrig M.V., Hermanowicz N. Cannabinoid rescue of striatal progenitor cells in chronic Borna disease viral encephalitis in rats. Journal of Neurovirology 2008, 14:252-260.
83. Stark-Adamec C., Pihl R.O., Adamec R.E. Contributions of individual differences to subjective intoxication. Psychological Reports 1980, 47:863-869.
84. Stephans S.E., Yamamoto B.K. Methamphetamine-induced neurotoxicity: roles for glutamate and dopamine efflux. Synapse 1994, 17:203-209.
85. Sulzer D., Sonders M.S., Poulsen N.W., Galli A. Mechanisms of neurostransmitter release by amphetamines: A review. Progress in Neurobiology 2005, 75:206-233.
86. Sun Y., Alexander S.P., Garle M.J., Gibson C.L., Hewitt K., Murphy S.P., et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. British Journal of Pharmacology 2007, 152:734-743.
87. Tanda G., Loddo P., Di Chiara G. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol. European Journal of Pharmacology 1999, 376:23-26.
88. Tanda G., Pontieri F.E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997, 276:2048-2050.
89. 1 receptors in the rat central nervous system. Neuroscience 1998, 83:393-411.
90. van der Stelt M., Di Marzo V. Cannabinoid receptors and their role in neuroprotection. Neuromolecular Medicine 2005, 7:37-50.
91. Van Sickle M.D., Duncan M., Kingsley P.J., Mouihate A., Urbani P., Mackie K., et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005, 310:329-332.
92. Volkow N.D., Chang L., Wang G.J., Fowler J.S., Ding Y.S., Sedler M., et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. American Journal of Psychiatry 2001, 158:2015-2021.
93. Wechsberg W.M., Luseno W., Riehman K., Karg R., Browne F., Parry C. Substance use and sexual risk within the context of gender inequality in South Africa. Substance Use and Misuse 2008, 43:1186-1201.
94. Winters B.D., Saksida L.M., Bussey T.J. Object recognition memory: neurobiological mechanisms of encoding, consolidation and retrieval. Neuroscience and Biobehavioral Reviews 2008, 32:1055-1070.
95. Yamamoto B.K., Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. Journal of Pharmacology and Experimental Therapeutics 1998, 287:107-114.
96. 1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice. Psychopharmacology (Berl) 2009, 204:203-211.